BioMarin Pharmaceutical (BMRN) Getting Somewhat Favorable Press Coverage, Analysis Finds
Headlines about BioMarin Pharmaceutical (NASDAQ:BMRN) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. BioMarin Pharmaceutical earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.6261465805131 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the media stories that may have impacted Accern’s rankings:
- BioMarin Pharma (BMRN) Says FDA Isn’t Planning Advisory Committee Meeting for Pegvaliase BLA (streetinsider.com)
- BioMarin Pharmaceutical Inc. (BMRN) Stock Rating Reaffirmed by BMO Capital Markets (americanbankingnews.com)
- BioMarin Pharmaceutical : FDA Not Currently Planning to Hold Advisory Committee Meeting for BioMarin’s Pegvaliase Biologics License Application (BLA) (4-traders.com)
- BioMarin Pharmaceutical Inc. (BMRN) Earns Sector Perform Rating from Analysts at Royal Bank Of Canada (americanbankingnews.com)
- BioMarin Pharma (BMRN) Says FDA Isn’t Planning Advisory Committee Meeting for Pegvaliase BLA – StreetInsider.com (streetinsider.com)
Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) opened at 91.91 on Friday. The firm has a 50-day moving average price of $86.49 and a 200-day moving average price of $89.56. The company’s market cap is $16.11 billion. BioMarin Pharmaceutical has a 1-year low of $78.42 and a 1-year high of $101.27.
BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.01. The business had revenue of $317.50 million for the quarter, compared to the consensus estimate of $311.41 million. BioMarin Pharmaceutical had a negative return on equity of 5.77% and a negative net margin of 15.54%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the business posted ($2.61) earnings per share. On average, equities analysts expect that BioMarin Pharmaceutical will post ($0.71) EPS for the current year.
Several brokerages have issued reports on BMRN. BidaskClub cut BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Stifel Nicolaus reissued a “buy” rating and issued a $107.00 target price on shares of BioMarin Pharmaceutical in a research report on Friday, August 4th. Wedbush reissued a “neutral” rating and issued a $108.00 target price on shares of BioMarin Pharmaceutical in a research report on Monday, August 7th. Evercore ISI began coverage on BioMarin Pharmaceutical in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $100.00 target price on the stock. Finally, Zacks Investment Research cut BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and fifteen have given a buy rating to the company. BioMarin Pharmaceutical presently has an average rating of “Hold” and an average price target of $109.09.
In other news, EVP George Eric Davis sold 9,844 shares of the firm’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $96.60, for a total value of $950,930.40. Following the transaction, the executive vice president now owns 93,425 shares in the company, valued at $9,024,855. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Brian Mueller sold 2,671 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $100.00, for a total value of $267,100.00. Following the completion of the transaction, the senior vice president now owns 15,556 shares in the company, valued at approximately $1,555,600. The disclosure for this sale can be found here. In the last 90 days, insiders sold 27,515 shares of company stock worth $2,568,030. Company insiders own 2.50% of the company’s stock.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.